NASDAQ:UBXUnity Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Unity Biotechnology Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $10.66 +0.15 (+1.43 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$10.35Now: $10.66▼$11.2150-Day Range$7.60MA: $8.74▼$10.2352-Week Range$4.62Now: $10.66▼$11.21Volume857,982 shsAverage Volume293,077 shsMarket Capitalization$554.75 millionP/E RatioN/ADividend YieldN/ABeta0.42 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingUnity Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.25, Unity Biotechnology has a potential upside of 136.9% from its current price of $10.66.Amount of Analyst CoverageUnity Biotechnology has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesUnity Biotechnology has received 129 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUnity Biotechnology has received 123 “underperform” votes. (Add your “underperform” vote.)Community SentimentUnity Biotechnology has received 51.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote “Outperform” if you believe UBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUnity Biotechnology does not currently pay a dividend.Dividend GrowthUnity Biotechnology does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Unity Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders37.30% of the stock of Unity Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.56% of the stock of Unity Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Unity Biotechnology are expected to grow in the coming year, from ($1.97) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unity Biotechnology is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unity Biotechnology is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.75 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:UBX Previous Symbol CUSIPN/A CIK1463361 WebN/A PhoneN/ADebt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees94 Outstanding Shares52,040,000Market Cap$554.75 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $10.66 +0.15 (+1.43 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive UBX News and Ratings via Email Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter. Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions How has Unity Biotechnology's stock been impacted by COVID-19 (Coronavirus)? Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UBX stock has increased by 97.8% and is now trading at $10.66. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Unity Biotechnology? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Unity Biotechnology. When is Unity Biotechnology's next earnings date? Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Unity Biotechnology. How were Unity Biotechnology's earnings last quarter? Unity Biotechnology Inc (NASDAQ:UBX) posted its quarterly earnings results on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.51) by $0.13. View Unity Biotechnology's earnings history. What price target have analysts set for UBX? 4 Wall Street analysts have issued 1-year price objectives for Unity Biotechnology's stock. Their forecasts range from $13.00 to $35.00. On average, they anticipate Unity Biotechnology's share price to reach $25.25 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View analysts' price targets for Unity Biotechnology. Has Unity Biotechnology been receiving favorable news coverage? Press coverage about UBX stock has been trending very positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next few days. View the latest news about Unity Biotechnology. Are investors shorting Unity Biotechnology? Unity Biotechnology saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 4,670,000 shares, an increase of 8.1% from the June 15th total of 4,320,000 shares. Based on an average trading volume of 288,500 shares, the short-interest ratio is currently 16.2 days. Currently, 18.6% of the shares of the stock are sold short. View Unity Biotechnology's Current Options Chain. Who are some of Unity Biotechnology's key competitors? Some companies that are related to Unity Biotechnology include TG Therapeutics (TGTX), Genus (GNS), Karuna Therapeutics (KRTX), Progyny (PGNY), Option Care Health (OPCH), ProShares UltraShort DJ-UBS Commodity (CMD), Cantel Medical (CMD), Nanosonics (NAN), Kodiak Sciences (KOD), Udg Healthcare (UDHCF), Glaukos (GKOS), Turning Point Therapeutics (TPTX), Integer (ITGR), Cronos Group (CRON) and CENTRIC HEALTH (CHH). View all competitors. What other stocks do shareholders of Unity Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include Canopy Growth (CGC), NIO (NIO), Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.Com (JD), Sorrento Therapeutics (SRNE) and Advanced Micro Devices (AMD). Who are Unity Biotechnology's key executives? Unity Biotechnology's management team includes the following people: Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)Dr. Anirvan Ghosh, Director & CEO (Age 56)Dr. Jan M. van Deursen, FounderDr. Judith Campisi, Founder When did Unity Biotechnology IPO? (UBX) raised $85 million in an IPO on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager. What is Unity Biotechnology's stock symbol? Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX." Who are Unity Biotechnology's major shareholders? Unity Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (0.42%), Asymmetry Capital Management L.P. (0.23%), Bessemer Group Inc. (0.20%), Moloney Securities Asset Management LLC (0.04%), SG Americas Securities LLC (0.04%) and ProShare Advisors LLC (0.03%). Which institutional investors are selling Unity Biotechnology stock? UBX stock was sold by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, UBS Group AG, Russell Investments Group Ltd., and Investors Financial Group LLC. Which institutional investors are buying Unity Biotechnology stock? UBX stock was bought by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P., Bessemer Group Inc., SG Americas Securities LLC, and ProShare Advisors LLC. How do I buy shares of Unity Biotechnology? Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Unity Biotechnology's stock price today? One share of UBX stock can currently be purchased for approximately $10.66. How big of a company is Unity Biotechnology? Unity Biotechnology has a market capitalization of $554.75 million. Unity Biotechnology employs 94 workers across the globe. This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
